H.C. Wainwright lowered the firm’s price target on Viridian Therapeutics to $27 from $37 and keeps a Buy rating on the shares. The firm is taking a more conservative stance on thyroid eye disease market growth based on what it has seen from Tepezza of late.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRDN: